Previous studies have shown that obstructive sleep apnea syndrome is associated with metabolic disorders and diabetes. However, it is not clear whether the course of obstructive sleep apnea improves metabolic parameters.
The aim of this study was to evaluate the effect of CPAP (CPAP) — a continuous positive pressure artificial ventilation regimen – on glycemic control in patients with cardiovascular diseases and obstructive sleep apnea.
Cardiovascular 888 cardiovascular system heart-Save (save). All patients had stable cardiovascular diseases and obstructive sleep apnea. Patients were randomly assigned to the group of sipap and conventional therapy or only habitual therapy.
Patients were measured for glycated hemoglobin (HbA1c) at the beginning of the study, at 6 months, at 2 and 4 years.
The average follow-up period was 4.3 years.
During the follow-up period in the group of patients with diabetes (N = 274), there were no significant differences in HbA1c, glycemic control, or use of antidiabetic drugs between the sipap group and the control group.
There were also no significant differences between the groups for the above indicators and the incidence of diabetes in patients with prediabetes (N = 452).
According to the results of the study, in patients with cardiovascular diseases and obstructive sleep apnea syndrome, sipap therapy has not been shown to improve glycemic control in patients with diabetes or pre-diabetes or reduce the risk of developing diabetes.
Source: Kelly A. Loeffler, Emma Healy, Ruth fried, et al. Diabetes Care Aug 2020, 43 (8) 1859-1867; DOI: 10.2337/dc19-2006.